The present invention relates to a compound or a pharmacologically acceptable salt thereof that has an excellent antagonistic effect on a neurokinin NK1 receptor, a neurokinin NK2 receptor, and a muscarine M3 receptor and is useful as a therapeutic agent for bronchial asthma, chronic obstructive pulmonary disease, or the like.A compound represented by general formula (I):[whereinR1 represents a hydrogen atom, a C1-C6 alkyl group, or the like； R2 represents a hydrogen atom, a C1-C6 alkyl group, or the like； R3 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, or the like； R4 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, or the like； L1 represents a C1-C10 alkylene group or the like； L2 represents a carbonyl group, a group represneted by the formula -N(R5)-C(=O)-, a group represented by the formula -C(=O)-N(R5)-, or the like； R5 represents a hydrogen atom, a C1-C6 alkyl group, or the like； E represents a phenylene group that may be substituted with 1 to 4 group(s) independently selected from Substituent Group A, or the like； m is an integer of 1 to 4； n is an integer of 0 to 4； p is an integer of 0 to 2； q is an integer of 1 to 10； r is 1 or 2； s is 0 or 1； and Substituent Group A represents the group consisting of a halogen atom, a C1-C6 alkyl group, C1-C6 halogenated alkyl group, or the like] or a pharmacologically acceptable salt thereof.
